April 24, 2018 / 12:59 PM / 5 months ago

BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial

April 24 (Reuters) - Alder Biopharmaceuticals Inc:

* ALDER BIOPHARMACEUTICALS® PRESENTS NEW 12-MONTH DATA OF EPTINEZUMAB IN PROMISE 1 PHASE 3 TRIAL SHOWING LONG-TERM REDUCTION IN EPISODIC MIGRAINE

* ALDER BIOPHARMA - DATA PRESENTED AT AAN ANNUAL MEETING DEMONSTRATE EPTINEZUMAB FURTHER REDUCES MIGRAINE RISK FOLLOWING 3RD, 4TH QUARTERLY INFUSIONS

* ALDER BIOPHARMACEUTICALS INC - MORE THAN 50% OF PATIENTS ACHIEVED A 75% REDUCTION OR GREATER OF MIGRAINE DAYS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below